Geisinger Clinic Annual Progress Report: 2011 Nonformula Grant
|
|
- Milo Stevenson
- 5 years ago
- Views:
Transcription
1 Geisinger Clinic Annual Progress Report: 2011 Nonformula Grant Reporting Period July 1, 2012 June 30, 2013 Nonformula Grant Overview The Geisinger Clinic received $1,000,000 in nonformula funds for the grant award period June 1, 2012 through May 31, Accomplishments for the reporting period are described below. Research Project: Project Title and Purpose Diagnostic-Prognostic Testing in Patients at High Risk for Esophageal Cancer The purpose of this project is to clinically validate a diagnostic-prognostic test for esophageal cancer, which will accurately diagnose at a premalignant stage and predict which patients are at high risk for esophageal cancer to enable early, preventative therapy. A prototype test has been developed and proof-of-concept of the testing technology has been established in collaborative work by Geisinger and Cernostics. The project aims to perform clinical validation studies in a training cohort and two independent validation cohorts of esophageal biopsies with clinical outcome data from Geisinger, University of Pittsburgh and University of Pennsylvania to select diagnostic and prognostic classifiers and to establish the sensitivity, specificity and positive and negative predictive values of the diagnostic-prognostic test for patients at high risk for esophageal cancer. Anticipated Duration of Project 6/1/2012 5/31/2014 Project Overview The broad objective of the research is to clinically validate a diagnostic and prognostic test that accurately assigns diagnosis and predicts risk of developing esophageal cancer. The test is a spatial systems biology-based approach to anatomic pathologic testing. The test employs multiplexed fluorescence labeling of tumor system biomarkers, including malignant, immune and stromal processes in anatomic pathology specimens with digital imaging and image analysis to quantify biomarker expression and spatial relationships between biomarkers in the context of tissue morphology. This is coupled to classifier software to integrate biomarker data with morphology data and clinical data to produce diagnostic and prognostic scores. These scores will be used to accurately diagnose and predict the risk of developing esophageal cancer in individual patients to enable early treatment. A prototype test has been collaboratively developed by Geisinger (lead applicant) and Cernostics, Inc. (small business collaborator) as a proof-ofconcept. As a next step, a consortium of investigators will perform retrospective clinical Therapeutics Page 1
2 validation studies of the test towards the long term goal of commercializing the test via a CLIAcertified laboratory. The test will be performed first in a training cohort of formalin-fixed paraffin-embedded esophageal biopsies with clinical data from Geisinger using Cernostics spatial systems biology technology, and diagnostic and prognostic classifiers will be developed. The test, including the classifiers, will then be performed in two independent validation patient cohorts from the University of Pittsburgh and the University of Pennsylvania to determine specificity, sensitivity and positive and negative predictive values of the diagnostic-prognostic test. The specific research aims are, 1) Determine the performance of the prototype test in stratifying patients according to diagnosis and predicting risk for esophageal cancer in a retrospective training patient cohort; and 2) Validate the diagnostic and prognostic performance of the optimized diagnostic-prognostic test in two independent retrospective patient cohorts. The training and validation cohorts represent both urban and rural populations and are designed to reach the maximum number of the underserved and will ensure a significant statewide impact on the health of Pennsylvanians. Paralleling the proposed project, Cernostics and Geisinger will perform further analytical validation studies on the test. The test will be commercialized by Cernostics and will be offered as a service to pathologists and gastroenterologists to guide individualized patient management to help prevent the development of esophageal cancer. Principal Investigator Jeffrey W. Prichard, DO Director of Surgical Pathology Geisinger Medical Laboratory 100 North Academy Avenue Danville, PA Other Participating Researchers Jinhong Li, MD, PhD; David L. Diehl, MD employed by Geisinger Clinic Rebecca J. Critchley-Thorne, PhD; Bruce Campbell, MS employed by Cernostics, Inc. Gary W. Falk, MD, MSc; Anil K. Rustgi, MD; Nirag Jhala, MD, PhD employed by the University of Pennsylvania Jon M. Davison, MD; Chakra Chennubhotla, Ph.D. employed by the University of Pittsburgh Blair A. Jobe, MD; Ali H. Zaidi, MD employed by West Penn Allegheny Health System Yi Zhang, Ph.D. consultant statistician Expected Research Outcomes and Benefits The project employs a testing technology for which Geisinger Health System and Cernostics have demonstrated proof-of-concept. The investigators have selected a comprehensive panel of diagnostic and prognostic biomarkers, many of which have established significance in diagnosing the stages of Barrett s esophagus and in predicting risk for esophageal cancer. Therefore, the expected research outcomes of the project are classifiers based on optimal sets of biomarker, morphology and clinical data that can accurately assign diagnosis and predict whether a patient will develop high grade dysplasia or esophageal cancer and also estimate the Therapeutics Page 2
3 sensitivity, specificity and overall accuracy of the diagnostic-prognostic test. It is expected that the test will have high sensitivity and specificity and high positive and negative predictive values based on the known diagnostic and prognostic significance of the panel of biomarkers and based on the high stringency of feature selection for the classifiers. It is also expected that the research will identify a key set of biomarkers and related molecular pathways involved in the progression of Barrett s esophagus to esophageal cancer, which will lead to a better understanding of the biology and behavior of esophageal cancer and aid in the design of new therapeutic agents to prevent and treat esophageal cancer. The diagnostic utility of the test will improve health status by increasing the accuracy of pathological diagnosis, thus reducing the number of repeat endoscopies and biopsies that patients with Barrett s esophagus must currently undergo, particularly for patients who are initially diagnosed as indefinite/indeterminate for dysplasia. The prognostic utility of the test will improve health status by identifying patients at high risk for developing esophageal cancer early in the disease progression when treatments such as endoscopic mucosal resection and radiofrequency ablation can be applied to effectively prevent development of cancer. The prognostic utility will also identify low risk patients, who will not develop esophageal cancer, and who can be spared unnecessary endoscopies, biopsies and treatments. The expected benefits of the project include; significant improvements in diagnostic and prognostic accuracy to prevent delays in treatment of patients at high risk for esophageal cancer, and a reduction in unnecessary and costly endoscopies and biopsies. This individualized approach will benefit patients by reducing the incidence and mortality associated with esophageal adenocarcinoma and will benefit health care systems by targeting treatments and screenings to the high-risk patients who need them. Summary of Research Completed Specific Aim 1 - Milestones for period 7/1/12 6/30/13: 1: Biomarker panel stained, imaged and quantified on 220 esophagus biopsies, 2: Selection of optimal panel of approx of biomarker features, morphology and clinical data features to assign diagnosis and prognosis, 3: Automated classifier algorithm to integrate optimal set of data features into diagnostic and prognostic indices. Progress towards achieving the milestones associated with specific aim 1 for this project period is described below. Geisinger Clinic cohort for retrospective training study: The investigators at Geisinger Clinic sent tissue sections from 211 Barrett s cases to Cernostics to be stained, imaged and analyzed during this project period. This brings the total cohort size to 470 cases from 215 patients with Barrett s esophagus (case collection for this cohort began before the start of the project). The cohort from Geisinger Clinic is summarized in Table 1. The tissues were reviewed by a gastrointestinal pathologist to confirm diagnosis. Elements of deidentified clinical and pathological data were also provided. Additional data elements are being extracted from the electronic medical records and will be de-identified for use in the study. The Therapeutics Page 3
4 investigators have also continued work on a relational database to store the de-identified Barrett s data extracted from various clinical databases at Geisinger. Selection of Prognostic Features and Prognostic Classifier Algorithm: Cernostics investigators have continued to develop and refine their image analysis software for use in the project. Figure 1A shows whole slide digital images of an example Barrett s biopsy labeled with the traditional histologic stain (Hematoxylin and Eosin) and labeled by 4-color multiplexed immunofluorescence for Barrett s biomarkers. Cernostics has developed image analysis masks that segment Barrett s biopsies into subcellular structures (nuclei, cytoplasm and plasma membrane) and tissue structures such as surface epithelium, glands, metaplastic cells, stroma, as shown in Figure 1B. These software tools allow measurement of specific biomarkers and morphology measurements to be made within each of these specific subcellular and tissue compartments (summarized in Figure 1C). The investigators have worked closely with an independent consultant statistician, Yi Zhang, Ph.D. to develop and test preliminary prognostic classifiers to stratify patients according to risk of developing high grade dysplasia (HGD) or esophageal cancer (EAC). 14 protein biomarkers were measured by image analysis in whole slide images of 241 Barrett s biopsies from 192 patients. Multiple measurements were made per biomarker, resulting in a total of 270 biomarker measurements extracted from each biopsy. Each measurement was summarized as 7 statistics, i.e. the 270 features produced 1,890 statistics per biopsy. Development of HGD or EAC was considered the high risk event and the low risk group was used as censoring. Patients with baseline HGD are more likely to develop EAC, and to develop it faster, than patients with lower baseline diagnosis, which is accounted for in the statistical analyses of the data. 3 different COX models were developed for each biomarker measurement/statistic: i. Univariate with each biomarker measurement/statistic, ii. Univariate adjusted by diagnosis (HGD vs all others), iii. Univariate adjusted by diagnosis, age, gender and race. 783 biomarker measurement/statistics were significantly associated with risk and 389 of the 783 significant biomarker measurement/statistics were associated with risk independently of diagnosis. All 783 biomarker measurement/statistics associated with risk were evaluated in multivariate analysis since diagnosis is associated with risk of progression in Barrett s. Age, gender and race were not significantly associated with risk of progression in this data set and were not adjusted for in the subsequent multivariate Cox modeling. The most significant biomarker measurement/statistics were then used in COX proportional hazard modeling. The top 5, 10, 15,, 50 biomarker measurement/statistics were evaluated. Leave-one-out cross validation (LOOCV) was performed by setting 1 test case aside and using all the remaining cases as a training set to select biomarker measurement/statistics as described above. The final prediction model was built using a Cox model that uses the selected biomarker measurement/statistics on the training set. This model was applied on 1 test case at a time to calculate the probability of remaining high risk free at 2, 3 and 4 years. This process was repeated until each case was treated as the test case once. At the end of LOOCV each case had an assigned probability of remaining high risk free at 2 years, 3 years and 4 years. C-indices were then calculated to assess the predictive power of the classifiers based on increasing numbers of biomarker measurement/statistics and at the 3 time points. Leave-one-out-cross-validation (LOOCV) is a method to assess how the prognostic classifier will generalize to an independent set. Each biopsy is used as a validation case (i.e. the one left Therapeutics Page 4
5 out), while the remaining biopsies are used as training set. This is repeated until all biopsies have been used as the validation case (i.e. all biopsies have been the one left out). The validation results are averaged across the multiple rounds of cross validation to produce the C-index, which indicates overall discrimination power of the classifiers across the cohort. Kaplan-Meier survival curves were plotted with one probability cutoff, which stratifies patients into low and high risk groups, and with two cutoffs, which stratify patients into low, intermediate and high risk groups. Results from the prognostic classifier testing are shown in Figure 2. A prognostic classifier based on 25 biomarker measurement/statistics derived from 5 biomarkers and DNA measurements with a single cutoff at 0.6 stratifies patients into two risk groups (low or high) with hazard ratio 7.2, p value <0.001, sensitivity of 64% and specificity of 87% (Figure 2B). This translates into 64% of the high risk cases being accurately classified and 87% of the low risk cases being accurately classified. This preliminary classifier identifies high risk patients who would be considered low risk by current standard pathology. The position of the classifier cutoff can be varied, which influences sensitivity and specificity, as shown in Figure 2A-C. The classifier with two cutoffs stratifies patients into 3 risk groups (low, intermediate or high) with hazard ratio of 12.2 (low versus high) and 3.58 (low versus intermediate) and p value of < (Figure 2D). Receiver operating characteristic (ROC) curve is shown in Figure 2E. The ROC curve illustrates the performance of the classifier system as its cutoff/threshold is varied. The ROC curve was created by plotting the true positive rate versus the false positive rate at various cutoff/threshold settings. Specific Aim 2 - Milestone for period 7/1/12 6/30/13: Construction of validation cohort of approx Barrett s esophagus biopsies from 400 patients with relevant clinicopathological data. 400 existing patient samples and de-identified data will be collected 6/1/12 6/30/13. Progress towards achieving the milestone associated with specific aim 2 for this project period is described below. University of Pittsburgh Cohort for Validation Study: The investigators at the University of Pittsburgh performed a retrospective search of the electronic medical record to identify patients who had undergone upper gastrointestinal endoscopy with biopsies by using natural language search capabilities in our laboratory information system CoPath. A set of biopsies representing over 20,000 individual patients and over 32,000 individual encounters (an encounter is a set of biopsies) were identified. There were over 5,300 patients with more than one biopsy. The median clinical surveillance interval (time between first and last set of biopsies for a given patient with more than one biopsy) is approximately 2 years (mean, approximately 3.5 years). The diagnosis of all 32,000 encounters were classified based on the degree of dysplasia (no dysplasia up to carcinoma) and the presence or absence of Barrett s esophagus. Of these, there were over 9,600 patients with a diagnosis of Barrett s esophagus and over 3,000 patients with high grade dysplasia or adenocarcinoma (many with only a single biopsy). The investigators at University of Pittsburgh have sent samples from a total of 37 cases from 31 patients to Cernostics to be stained, imaged and analyzed. The cohort status is summarized in Therapeutics Page 5
6 Table 1. The investigators are currently utilizing the database that they constructed to select the remainder of the Barrett s cohort and have identified an additional 62 patients for the study, e.g. patients with Barrett s esophagus who did not progress to high grade dysplasia or carcinoma during surveillance; patients with prevalent high grade dysplasia or adenocarcinoma; patients who developed high grade dysplasia or adenocarcinoma during surveillance. The University of Pittsburgh investigators continue to query the dataset to identify additional patients/cases for the cohort. University of Pennsylvania Cohort for Validation Study: A query of Barrett s pathology results has been done at the University of Pennsylvania. 21 cases from 4 patients have been sent to Cernostics to be stained, imaged and analyzed thus far. The cohort status is summarized in Table 1. The following additional patients/cases have been identified and will be sent to Cernostics: 42 patients that are non-progressors after 5 or more years of follow up, 6 patients that have progressed from no dysplasia/indefinite and/or low grade dysplasia to high grade dysplasia and/or adenocarcinoma and 13 patients with high grade dysplasia. The University of Pennsylvania investigators continue to query the dataset to identify additional patients/cases for the cohort. Therapeutics Page 6
7 Tables and Figures. Table 1. Summary of Barrett s Cohorts at Each Clinical Institution Institution Cases Patients Low Risk Patients High Risk Patients High Recur Patients HGD/ EAC Patients Geisinger Clinic University of Pittsburgh University of Pennsylvania Definitions: Case is a set of biopsies in a single paraffin block and some patients have multiple cases from different parts of the esophagus or from different surveillance time points in the cohorts; Low risk patients did not develop HGD/EAC over the course of 5 years surveillance; High risk patients developed HGD/EAC during surveillance; High recur patients were treated for HGD/EAC then entered surveillance and had a recurrence of HGD/EAC. Therapeutics Page 7
8 Figure 1. Figure 1. Summary of Cernostics Image Analysis Tools Developed and/or Modified During this Project Period. A: Whole slide images of histologically-stained Barrett s biopsy and multiplexed fluorescence-stained Barrett s biopsy, B: Tissue and cellular image analysis masks, C: Biomarker and morphology measurements made on each Barrett s biopsy. Therapeutics Page 8
9 Figure 2. Figure 2. Preliminary Prognostic Classifier Distinguishes High Risk from Low Risk Barrett s Patients. A prognostic classifier based on 25 measurements/statistics derived from 5 biomarkers and DNA measurements with a single cutoff stratifies patients according to two risk groups (low or high). The significance and performance of the classifier (measured by hazard ratio, p value, sensitivity and specificity) varies depending on the position of the classifier cutoff (A (cutoff 0.4), B (cutoff 0.6), C (cutoff 0.9). The use of two cutoffs produces a 3 tier classifier (D) that stratifies patients according to three risk groups (low, intermediate and high). Receiver operating characteristic curve is shown (E) that has area under the curve of Therapeutics Page 9
Learning Objectives:
Crescent City GI Update 2018 Ochsner Clinic, NOLA Optimizing Endoscopic Evaluation of Barrett s Esophagus What Should I Do in My Practice? Gregory G. Ginsberg, M.D. Professor of Medicine University of
More informationCarnegie Mellon University Annual Progress Report: 2011 Nonformula Grant
Carnegie Mellon University Annual Progress Report: 2011 Nonformula Grant Reporting Period July 1, 2012 June 30, 2013 Nonformula Grant Overview Carnegie Mellon University received $983,783 in nonformula
More informationManagement of Barrett s Esophagus. Case Presentation
Management of Barrett s Esophagus Lauren B. Gerson MD, MSc Associate Clinical Professor, UCSF Director of Clinical Research Gastroenterology Fellowship Program California Pacific Medical Center San Francisco,
More informationQuality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2008 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2011 December 31, 2011 Formula Grant Overview The National Surgical
More informationCurrent Management of Low-Grade Dysplasia in Barrett Esophagus
Current Management of Low-Grade Dysplasia in Barrett Esophagus Gary W. Falk, MD, MS Dr Falk is a professor of medicine in the Division of Gastroenterology at the University of Pennsylvania Perelman School
More informationQuality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
More informationBarrett s Esophagus: Old Dog, New Tricks
Barrett s Esophagus: Old Dog, New Tricks Stuart Jon Spechler, M.D. Chief, Division of Gastroenterology, VA North Texas Healthcare System; Co-Director, Esophageal Diseases Center, Professor of Medicine,
More informationBarrett s Esophagus. Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI
Barrett s Esophagus Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI A 58 year-old, obese white man has had heartburn for more than 20 years. He read a magazine
More informationWhat s New in the Management of Esophageal Disease
What s New in the Management of Esophageal Disease Philip O. Katz, MD Chairman, Division of Gastroenterology Einstein Medical Center Philadelphia Clinical Professor of Medicine Jefferson Medical College
More informationHistopathology of Endoscopic Resection Specimens from Barrett's Esophagus
Histopathology of Endoscopic Resection Specimens from Barrett's Esophagus Br J Surg 38 oct. 1950 Definition of Barrett's esophagus A change in the esophageal epithelium of any length that can be recognized
More informationAGA SECTION. Gastroenterology 2016;150:
Gastroenterology 2016;150:1026 1030 April 2016 AGA Section 1027 Procedural intervention (3) Upper endoscopy indications 3 6 Non-response of symptoms to a 4 8 week empiric trial of twice-daily PPI Troublesome
More informationACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus
ACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus Nicholas J. Shaheen, MD, MPH, FACG 1, Gary W. Falk, MD, MS, FACG 2, Prasad G. Iyer, MD, MSc, FACG 3 and Lauren Gerson, MD, MSc, FACG
More informationFinal Project Report Sean Fischer CS229 Introduction
Introduction The field of pathology is concerned with identifying and understanding the biological causes and effects of disease through the study of morphological, cellular, and molecular features in
More informationIs Radiofrequency Ablation Effective In Treating Barrett s Esophagus Patients with High-Grade Dysplasia?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Radiofrequency Ablation Effective
More informationLayered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue
Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to
More informationGregory G. Ginsberg, M.D.
Radiofrequency Ablation for Barrett s Esophagus with HGD Gregory G. Ginsberg, M.D. Professor of Medicine University of Pennsylvania School of Medicine Abramson Cancer Center Gastroenterology Division Executive
More informationMANAGEMENT OF BARRETT S RELATED NEOPLASIA IN 2018
MANAGEMENT OF BARRETT S RELATED NEOPLASIA IN 2018 Sachin Wani Medical Director Esophageal and Gastric Center Division of Gastroenterology and Hepatology University of Colorado Anschutz Medical Campus DISCLOSURES
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The National Surgical
More informationBarrett s esophagus. Barrett s neoplasia treatment trends
Options for endoscopic treatment of Barrett s esophagus Patrick S. Yachimski, MD MPH Director of Pancreatobiliary Endoscopy Assistant Professor of Medicine Division of Gastroenterology, Hepatology & Nutrition
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Transfer of Health Information and Interoperability 2019 COLLECTION TYPE:
More informationFaculty Disclosure. Objectives. State of the Art #3: Referrals for Gastroscopy (focus on common esophagus problems) 24/11/2014
State of the Art #3: Referrals for Gastroscopy (focus on common esophagus problems) Dr. Amy Morse November 2014 Faculty: Amy Morse Faculty Disclosure Relationships with commercial interests: Grants/Research
More informationMorphologic Criteria of Invasive Colonic Adenocarcinoma on Biopsy Specimens
ISPUB.COM The Internet Journal of Pathology Volume 12 Number 1 Morphologic Criteria of Invasive Colonic Adenocarcinoma on Biopsy Specimens C Rose, H Wu Citation C Rose, H Wu.. The Internet Journal of Pathology.
More informationCDx Diagnostics THE NEW STANDARD FOR QUALITY GI CARE
CDx Diagnostics THE NEW STANDARD FOR QUALITY GI CARE STUDYDESIGN 16 major academic GI centers participated in a double-blind, randomized, crossover study in which 160 high-risk patients undergoing BE surveillance
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The National Surgical
More informationNational Mesothelioma Virtual Bank 2017-Annual Face to Face Meeting ( Supported by CDC/NIOSH Grant U24OH009077
National Mesothelioma Virtual Bank 2017-Annual Face to Face Meeting (http://www.mesotissue.org) Supported by CDC/NIOSH Grant U24OH009077 Waqas Amin, MD Program Coordinator, NMVB Senior Research Scientist
More informationVital staining and Barrett s esophagus
Marcia Irene Canto, MD, MHS Baltimore, Maryland Vital staining or chromoendoscopy refers to staining of endoscopic tissue or topical application of chemical stains or pigments to alter tissue appearances
More informationManagement of Barrett s: From Imaging to Resection
Management of Barrett s: From Imaging to Resection Michael Wallace, MD, MPH, FACG Professor of Medicine Mayo Clinic Florida Goals of Endoscopic Evaluation in Barrett s Detect Barrett s and dysplasia Reduce/eliminate
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationAD (Leave blank) TITLE: Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients
AD (Leave blank) Award Number: W81XWH-12-1-0444 TITLE: Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients PRINCIPAL INVESTIGATOR: Mark A. Watson, MD PhD CONTRACTING ORGANIZATION:
More informationThe 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis
The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis Tieliu Shi tlshi@bio.ecnu.edu.cn The Center for bioinformatics
More informationRFA and Cyrotherapy for Esophageal Disease
RFA and Cyrotherapy for Esophageal Disease Daniel L. Miller MD Chief, General Thoracic Surgery WellStar Healthcare System/ Mayo Clinic Care Network Clinical Professor of Surgery Medical College of Georgia/
More informationHistory. Prevalence at Endoscopy. Prevalence and Reflux Sx. Prevalence at Endoscopy. Barrett s Esophagus: Controversy and Management
Barrett s Esophagus: Controversy and Management History Norman Barrett (1950) Chronic Peptic Ulcer of the Oesophagus and Oesophagitis Allison and Johnstone (1953) The Oesophagus Lined with Gastric Mucous
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The NSABP Foundation
More informationAndrogen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer
More informationThe presence of intestinal-type goblet cells (ITGCs) in
Goblet Cell Mimickers in Esophageal Biopsies Are Not Associated With an Increased Risk for Dysplasia Mamoun Younes, MD; Atilla Ertan, MD; Gulchin Ergun, MD; Ray Verm, MD; Margaret Bridges, MD; Karen Woods,
More informationGenomic Diversity in Barrett s esophagus predicts long term progression.., Soesterberg, Prof. dr. Sheila Krishnadath
Genomic Diversity in Barrett s esophagus predicts long term progression.., Soesterberg, Prof. dr. Sheila Krishnadath 14-03-2018 Esophageal squamous cell carcinoma Risk factors - Alcohol - Smoking - Male
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationBarrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD?
Barrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD? Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina 1 Outline What are the risks of progression
More informationEndoscopic Radiofrequency Ablation or Cryoablation for Barrett s Esophagus
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett s Esophagus Policy Number: 2.01.80 Last Review: 6/2018 Origination: 6/2012 Next Review: 6/2019 Policy Blue Cross and Blue Shield of Kansas
More informationAbstract. Background. Objective
Molecular epidemiology of clinical tissues with multi-parameter IHC Poster 237 J Ruan 1, T Hope 1, J Rheinhardt 2, D Wang 2, R Levenson 1, T Nielsen 3, H Gardner 2, C Hoyt 1 1 CRi, Woburn, Massachusetts,
More informationHistopathology: Cervical HPV and neoplasia
Histopathology: Cervical HPV and neoplasia These presentations are to help you identify basic histopathological features. They do not contain the additional factual information that you need to learn about
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationAblation for Barrett s Esophagus: Burn or Freeze
Ablation for Barrett s Esophagus: Burn or Freeze John R. Saltzman MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School Disclosures No relevant disclosures
More informationEstimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study
Thein et al. BMC Cancer (2018) 18:694 https://doi.org/10.1186/s12885-018-4620-2 RESEARCH ARTICLE Estimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study
More informationHiatal Hernias and Barrett s esophagus. Dr Sajida Ahad Mercy General Surgery
Hiatal Hernias and Barrett s esophagus Dr Sajida Ahad Mercy General Surgery Objectives Identify the use of different diagnostic modalities for hiatal hernias List the different types of hiatal hernias
More informationSurvival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer
Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer Jayashree Kalpathy-Cramer PhD 1, William Hersh, MD 1, Jong Song Kim, PhD
More informationDefinition of GERD American College of Gastroenterology
Definition of GERD American College of Gastroenterology GERD is defined as chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus DeVault et al. Am J
More informationEndoscopic Management of Barrett s Esophagus
Endoscopic Management of Barrett s Esophagus Sammy Ho, MD Director of Pancreaticobiliary Services and Endoscopic Ultrasound Montefiore Medical Center Barrett s Esophagus Consequence of chronic GERD Mean
More informationPresent Day Management of Barrett s Esophagus
Slide 1 Present Day Management of Barrett s Esophagus Kinnari R. Kher, M.D. Slide 2 Goals Risk factors for development of Barrett s esophagus Risks for progression to Esophageal Adenocarcinoma Current
More informationNew Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus
New Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus Prateek Sharma, MD Key Clinical Management Points: Endoscopic recognition of a columnar lined distal esophagus is crucial
More informationApplying Tissue Phenomics to Colorectal Clinical Questions
Applying Tissue Phenomics to Colorectal Clinical Questions International Symposium for Tissue Phenomics San Francisco October 2014 Peter Caie Senior Research Fellow University of St Andrews Systems Pathology
More informationInterpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment. Lorcan Sherry, CSO OracleBio
Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment Lorcan Sherry, CSO OracleBio Company Overview OracleBio is a specialised CRO providing
More informationMolecular Testing for the Management of Pancreatic Cysts or Barrett Esophagus
Molecular Testing for the Management of Pancreatic Cysts or Barrett Esophagus Policy Number: 2.04.52 Last Review: 8/2018 Origination: 5/2008 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas
More informationEverything Esophagus: Barrett s Esophagus. Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina
Everything Esophagus: Barrett s Esophagus Nicholas Shaheen, MD, MPH Center for Esophageal Diseases and Swallowing University of North Carolina The Most Important Thing Stayed the Same Adenocarcinoma A
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationIn 1998, the American College of Gastroenterology issued ALIMENTARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1232 1236 ALIMENTARY TRACT Effects of Dropping the Requirement for Goblet Cells From the Diagnosis of Barrett s Esophagus MARIA WESTERHOFF,* LINDSEY HOVAN,
More informationPrognostic value of tumor length in predicting survival for patients with esophageal cancer
Original Article Prognostic value of tumor length in predicting survival for patients with esophageal cancer Haijing Wang 1, Liangwen Bi 2, Lizhen Zhang 2, Weiyong Zhao 2, Min Yang 1,3, Xinchen Sun 1 1
More informationAmerican Journal of Gastroenterology. Volumetric Laser Endomicroscopy Detects Subsquamous Barrett s Adenocarcinoma
Volumetric Laser Endomicroscopy Detects Subsquamous Barrett s Adenocarcinoma Journal: Manuscript ID: AJG-13-1412.R1 Manuscript Type: Letter to the Editor Keywords: Barrett-s esophagus, Esophagus, Endoscopy
More informationThis medical position statement considers a series of
GASTROENTEROLOGY 2011;140:1084 1091 American Gastroenterological Association Medical Position Statement on the Management of Barrett s Esophagus The Institute Medical Position Panel consisted of the authors
More informationJoel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery
Joel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery Norman Barrett (1950) described the esophagus as: that part of the foregut, distal to the cricopharyngeal sphincter, which is lined
More informationChanges to the diagnosis and management of Barrett s Oesophagus
Changes to the diagnosis and management of Barrett s Oesophagus A review of the new BSG and NICE guidelines and best practice Anjan Dhar DM, MD, FRCPE, AGAF, MBBS (Hons.), Cert. Med. Ed Senior Lecturer
More information2018 Surgical Pathology Update: Diagnostic Pearls for the Practicing Pathologist - Volume II
Release Date: January 1, 15.25 AMA PRA Category 1 Credit(s) TM About This CME Teaching Activity This CME Activity is designed to provide a comprehensive review of soft tissue, gastrointestinal, genitourinary,
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
PathFinderTG Molecular Testing Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: PathFinderTG Molecular Testing Professional Institutional Original Effective
More informationSurgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database
Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department
More informationEndoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus Policy Number: Original Effective Date: MM.02.005 09/01/2010 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST Integration
More informationWhat Every Pathologist Wants the GI Nurse to Know (and how you can help us help you)
What Every Pathologist Wants the GI Nurse to Know (and how you can help us help you) Jonathan N. Glickman MD PhD Director, GI Pathology, Caris Diagnostics, Newton, MA Associate Professor of Pathology,
More informationTitle:COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis
Author's response to reviews Title:COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis Authors: Ewa Pomianowska (ewa.pomianowska@medisin.uio.no) Aasa R
More informationEditorial: Advanced endoscopic therapeutics in Barrett s neoplasia; where are we now and where are we heading?
Editorial: Advanced endoscopic therapeutics in Barrett s neoplasia; where are we now and where are we heading? Dr. Gaius Longcroft-Wheaton MB,BS, MD, MRCP(UK), MRCP(Gastro) Consultant gastroenterologist
More informationProtein Biomarkers for Screening, Detection, and/or Management of Prostate Cancer
Medical Policy Manual Laboratory, Policy No. 69 Protein Biomarkers for Screening, Detection, and/or Management of Prostate Cancer Next Review: October 2018 Last Review: December 2017 Effective: January
More informationUpdate on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.
1 Our speaker for this program is Dr. Anja Roden, an associate professor of Laboratory Medicine and Pathology at Mayo Clinic as well as consultant in the Anatomic Pathology Laboratory and co-director of
More informationOesophagus and Stomach update dysplasia and early cancer
Oesophagus and Stomach update dysplasia and early cancer Dr Tim Bracey STR teaching 13/4/16 Please check pathkids.com for previous talks One of the biggest units in the country (100 major resections per
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationHHS Public Access Author manuscript Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 March 01.
A Model Based on Pathologic Features of Superficial Esophageal Adenocarcinoma Complements Clinical Node Staging in Determining Risk of Metastasis to Lymph Nodes Jon M. Davison, MD 1, Michael S. Landau,
More informationBarrett s Esophagus: Ablate Everyone?
Nicholas J. Shaheen, MD, MPH, FACG Barrett s Esophagus: Ablate Everyone? Nicholas J. Shaheen, MD, MPH, FACG Center for Esophageal Diseases and Swallowing University of North Carolina Greetings from UNC,
More informationGENE EXPRESSION PROFILING AND PROTEIN BIOMARKERS FOR PROSTATE CANCER MANAGEMENT
CANCER MANAGEMENT Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationProton-pump inhibitor therapy and the development of dysplasia in patients with Barrett s oesophagus
Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett s oesophagus BARRETT S OESOPHAGUS is a premalignant condition, with dysplasia usually preceding the development of
More informationThe Wistar Institute of Anatomy and Biology Annual Progress Report: 2011 Nonformula Grant
The Wistar Institute of Anatomy and Biology Annual Progress Report: 2011 Nonformula Grant Reporting Period July 1, 2012 June 30, 2013 Nonformula Grant Overview The Wistar Institute of Anatomy and Biology
More informationDetection of Prostate Cancer Progression by Serum DNA Integrity
AD Award Number: TITLE: Detection of Prostate Cancer Progression by Serum DNA Integrity PRINCIPAL INVESTIGATOR: Dave S.B. Hoon, Ph.D. CONTRACTING ORGANIZATION: John Wayne Cancer Institute Santa Monica,
More informationDigital Pathology - moving on after implementation. Catarina Eloy, MD, PhD
Digital Pathology - moving on after implementation Catarina Eloy, MD, PhD Catarina Eloy, MD, PhD No conflict of interests to declare Pathology challenges today Maintaining high quality students interested
More informationMultiplex immunofluorescence for investigating the prognostic value of immune cells Chidozie Anyaegbu, PhD
Multiplex immunofluorescence for investigating the prognostic value of immune cells Chidozie Anyaegbu, PhD Catholic Health Australia Symposium Mater Hospital, Brisbane 1 st June 2018 Why colorectal cancer?
More informationDetection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique
Cancer and Clinical Oncology; Vol. 7, No. 1; 2018 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell
More informationRESEARCH COMMUNICATION
DOI:http://dx.doi.org/10.7314/APJCP.2012.13.1.199 RESEARCH COMMUNICATION Prognostic Significance of CYFRA21-1, CEA and Hemoglobin in Patients with Esophageal Squamous Cancer Undergoing Concurrent Chemoradiotherapy
More informationCorporate Medical Policy
Corporate Medical Policy Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_and_protein_biomarkers_for_diagnosis_and_risk_assessment_of_prostate_cancer
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationBarrett's Esophagus: Sorting Out the Controversy
Barrett's Esophagus: Sorting Out the Controversy Learning Objectives 1. Identify the challenges in screening for Barrett s esophagus 2. Demonstrate comprehension of the risk of progression of Barrett s
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationEarly detection and treatment for Esophageal Cancer in Africa
Early detection and treatment for Esophageal Cancer in Africa Dr Michael Mwachiro Tenwek Hospital NCI-IARC ESCC Tumor Workshop Where is Tenwek Hospital? Tenwek Nairobi Tenwek Hospital Identification of
More informationLog odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection
Original Article Log odds of positive lymph nodes is a novel prognostic indicator for advanced ESCC after surgical resection Mingjian Yang 1,2, Hongdian Zhang 1,2, Zhao Ma 1,2, Lei Gong 1,2, Chuangui Chen
More informationMedicare Advantage Medical Policy
Medicare Advantage Medical Policy Current Policy Effective Date: 1/1/18 Title: Endoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus Description/Background Barrett Esophagus and the
More informationCollege of American Pathologists. Pathology Performance Measures included in CMS 2012 PQRS
College of American Pathologists Pathology Performance Measures included in CMS 2012 PQRS Breast Cancer Resection Pathology Reporting Measure #99 pt category (primary tumor) and pn category (regional lymph
More informationCoordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma
Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,
More informationResearch Article Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma
BioMed Research International, Article ID 64568, 6 pages http://dx.doi.org/.55/24/64568 Research Article Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically
More informationResearch Article Early Esophageal Cancer Specific Survival Is Unaffected by Anatomical Location of Tumor: A Population-Based Study
Canadian Gastroenterology and Hepatology Volume 216, Article ID 613264, 7 pages http://dx.doi.org/1.1155/216/613264 Research Article Early Esophageal Cancer Specific Survival Is Unaffected by Anatomical
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-16-1-0737 TITLE: Developing a PTEN-ERG Signature to Improve Molecular Risk Stratification in Prostate Cancer PRINCIPAL INVESTIGATOR: Tamara Lotan CONTRACTING ORGANIZATION: Johns Hopkins
More informationMedical Policy Manual. Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010
Medical Policy Manual Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010 Section: Laboratory Last Reviewed Date: April 2014 Policy No: 61 Effective Date: July 1, 2014 IMPORTANT
More information